TARPON SPRINGS, Fla., June 2, 2025 - Allarity Therapeutics, Inc. (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company, has announced the enrollment of the first patient in its new Phase 2 clinical trial protocol for stenoparib. This trial focuses on the treatment of advanced, platinum-resistant or platinum-ineligible ovarian cancer. The study aims to evaluate the overall efficacy and safety of stenoparib, a dual PARP and WNT pathway inhibitor, and to enhance understanding of its modulation of the WNT signaling pathway, which is significant in the progression of ovarian and other cancers. The trial is structured to explore optimal dosing levels and aligns with the FDA's Project Optimus initiative, potentially informing future pivotal registration trials. Allarity plans to expedite approval processes for stenoparib and its DRP companion diagnostic by leveraging multiple regulatory pathways. The company anticipates significant clinical data by late summer 2026.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。